630422-99-0

Basic information

• Product Name: 1-chloro-7-fluoro-6-methoxyisoquinoline
• Synonyms: 1-chloro-7-fluoro-6-methoxyisoquinoline;EOS-61225
• CAS NO: 630422-99-0
• Molecular Formula: C10H7ClFNO
• Molecular Weight: 211.6200832
• Mol File: 630422-99-0.mol

Chemical Properties

• Boiling Point: 342.9±37.0 °C(Predicted)
• Appearance: /
• Density: 1.348±0.06 g/cm3(Predicted)
• PKA: 2.20±0.40(Predicted)
• CAS DataBase Reference: 1-chloro-7-fluoro-6-methoxyisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 1-chloro-7-fluoro-6-methoxyisoquinoline(630422-99-0)
• EPA Substance Registry System: 1-chloro-7-fluoro-6-methoxyisoquinoline(630422-99-0)

Safety Data

• Hazardous Substances Data: 630422-99-0(Hazardous Substances Data)

Usage

Type of compound

Aromatic compound

Contains

Chlorine, fluorine, and methoxy group

Usage

Intermediate in the synthesis of pharmaceuticals and agrochemicals

Potential use

Development of new drugs due to structural features and pharmacological properties

Application

Fluorescent probe in biological imaging studies

Application

Building block in organic synthesis

Value

Valuable in various scientific and industrial applications due to unique structure and properties

Upstream product

• 630424-79-2 (E)-3-(4-fluoro-3-methoxyphenyl) acrylic acid 
• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 
• 630422-98-9 7-fluoro-6-methoxyisoquinolin-1(2H)-one 
• 1409964-67-5 (E)-3-(4-fluoro-3-methoxyphenyl) acryloyl azide 

Relevant articles and documents

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Macrocyclic peptides are disclosed having the general formula: wherein R′, R3, R3′, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.